Ferric pyrophosphate citrate - Generic Drug Details

What are the generic sources for ferric pyrophosphate citrate and what is the scope of freedom to operate?

Ferric pyrophosphate citrate is the generic ingredient in two branded drugs marketed by Rockwell Medical Inc and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ferric pyrophosphate citrate has thirteen patent family members in eleven countries.

Summary for ferric pyrophosphate citrate

International Patents:	13
US Patents:	2
Tradenames:	2
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
What excipients (inactive ingredients) are in ferric pyrophosphate citrate?	ferric pyrophosphate citrate excipients list
DailyMed Link:	ferric pyrophosphate citrate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ferric pyrophosphate citrate

Constraining patent/regulatory exclusivity:

7,857,977

Dosage:

FOR SOLUTION;INTRAVENOUS

Constraining patent/regulatory exclusivity:

7,816,404

Dosage:

SOLUTION;INTRAVENOUS

Constraining patent/regulatory exclusivity:

7,816,404

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ferric pyrophosphate citrate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rockwell Medical Technologies, Inc.	Phase 3
Rockwell Medical Technologies, Inc.	Phase 2
Rockwell Medical Technologies, Inc.	Phase 1/Phase 2

See all ferric pyrophosphate citrate clinical trials

US Patents and Regulatory Information for ferric pyrophosphate citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No	7,816,404
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-002	Sep 4, 2015		DISCN	Yes	No
Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	212860-001	Mar 27, 2020		DISCN	Yes	No	7,816,404			Y
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No	7,857,977
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015		DISCN	Yes	No	7,816,404		Y

Expired US Patents for ferric pyrophosphate citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015	6,689,275
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015	6,779,468

International Patents for ferric pyrophosphate citrate

Country	Patent Number	Title	Estimated Expiration
Spain	2383713
Austria	E554754
Portugal	2016940
Croatia	P20120416
Japan	2009108027	METHOD FOR PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITION
Cyprus	1113903

Market Dynamics and Financial Trajectory of Ferric Pyrophosphate Citrate

Last updated: February 20, 2026

What is the current market landscape for Ferric Pyrophosphate Citrate (FPC)?

Ferric Pyrophosphate Citrate (FPC) is a ferric salt compound used primarily in dialysis to manage iron deficiency anemia (IDA) in chronic kidney disease (CKD) patients. It is marketed under the brand name Triferic. Since its FDA approval in 2015, FPC has gained regulatory approval in multiple regions but remains a niche product with a limited market size.

Regulatory Status and Approvals

• FDA (United States): Approved for use in hemodialysis patients to maintain iron stores and reduce the need for supplemental iron and erythropoiesis-stimulating agents (ESAs).
• European Union: Not yet approved.
• Other Jurisdictions: Limited approval, primarily under clinical development or experimental use.

Route to Market and Commercial Presence

FPC's commercialization focuses on dialysis clinics, targeted at reducing iron administration costs. It is administered via the dialysate during treatments, ensuring direct iron delivery.

Market Size Estimation (2022-2023)

The global dialysis population exceeds 2 million patients, with approximate annual growth of 4%. The subset eligible for FPC treatment, considering CKD-related anemia, is roughly 1.2 million.

Current market penetration is less than 10% of eligible patients, primarily in North America and select European clinics, limiting the current market size to approximately $50 million globally.

What factors influence the market dynamics of FPC?

Regulatory approvals shape the availability and geographic reach of FPC.

Clinical evidence supports incremental adoption, with recent studies confirming comparable efficacy to intravenous iron with fewer adverse events.

Reimbursement policies impact adoption, especially in the U.S., where Medicare and private insurers reimburse FPC through dialysis services.

Manufacturing capacity affects supply and pricing. As of 2023, production scale remains limited due to specialized synthesis processes.

Competitive landscape centers around intravenous iron formulations, which dominate the treatment regime. FPC's unique oral and dialysate administration offers advantages, but none have fully displaced intravenous options due to clinical inertia and cost considerations.

Market drivers:

• Rising prevalence of CKD (estimated 10% globally).
• Cost savings in iron supplementation strategies.
• Preference for less invasive administration routes.

Market barriers:

• Limited regulatory approvals outside the U.S.
• Slow clinical adoption due to established intravenous protocols.
• Higher pricing relative to generics of IV iron.

How does the financial trajectory look for FPC?

Revenue Trends:

• In 2022, FPC generated approximately $50 million globally.
• Projected compounded annual growth rate (CAGR) of 8-10% over the next five years, driven by increased CKD prevalence and expanding clinical adoption.
• Key markets: U.S., accounting for 70% of sales; Europe, 20%; other regions, 10%.

Pricing Strategy:

• FPC is priced at roughly $10-15 per dose, which is higher than generic IV iron formulations but reflects its targeted niche.

Cost Structure:

• Manufacturing costs are estimated at 30% of sales, with R&D expenses declining following initial approvals.
• Marketing efforts focused on dialysis clinics and nephrologists increase ongoing expenses.

Profitability Outlook:

• Break-even point projected within 3-4 years for manufacturers due to the high unit price and increasing adoption.
• Continued expansion relies on regulatory approvals in additional jurisdictions and replication of clinical efficacy data.

Investment and Development Pipeline:

• Several companies are exploring oral formulations of ferric compounds, aiming to capture a broader anemia market.
• Some firms are conducting phase 3 trials for FPC's use in non-dialysis CKD anemia, which could diversify revenue streams.

What are the key risks and opportunities?

Risks	Opportunities
Limited geographic approvals	Growing prevalence of CKD globally
Clinical adoption inertia	Potential new indications (e.g., non-dialysis anemia)
Competitive intravenous iron products	Cost savings in anemia management
Regulatory delays or rejections	Expansion into emerging markets

Conclusion

The financial trajectory of Ferric Pyrophosphate Citrate hinges on regulatory expansion, clinical adoption, and cost benefits relative to existing therapies. Market growth is moderate but steady, with potential for acceleration if approvals extend geographically and indications broaden.

Key Takeaways

• FPC is a niche iron therapy primarily used during dialysis to manage anemia.
• Its global market size remains small ($50 million), expanding at about 8-10% CAGR.
• Growth relies on approval in new territories, increased CKD prevalence, and recognition of its cost benefits.
• Revenue potential is constrained by existing competition from IV iron, but clinical advantages may enhance uptake.
• Larger opportunities may emerge with new formulations and off-label indications.

FAQs

1. What is the primary clinical advantage of Ferric Pyrophosphate Citrate?

   • It delivers iron directly through dialysate, reducing the need for IV iron and lowering adverse events.

2. Why is FPC’s market limited outside the U.S.?

   • Limited regulatory approvals and clinical adoption barriers restrict its use elsewhere.

3. How does FPC pricing compare to intravenous iron therapies?

   • FPC costs approximately $10-15 per dose, higher than generic IV iron formulations but justified by targeted delivery and safety profile.

4. What are the prospects for FPC's approval in Europe?

   • Pending submissions and favorable clinical data, European approval could expand market size significantly.

5. What innovation could boost FPC’s market growth?

   • Expanded indications, such as non-dialysis CKD anemia, and formulations allowing oral administration, could broaden its appeal.

---

References

[1] U.S. Food and Drug Administration. (2015). FDA approves Triferic for controlling anemia in dialysis patients. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-triferic-controlling-anemia-dialysis-patients

[2] Global dialysis population data. (2023). International Society of Nephrology. Retrieved from https://www.isn-online.org

[3] Market projection reports. (2023). GlobalData. "Iron therapies in CKD," 2023 outlook.